Want to see BLFS full AI Analyst Report?
Top Page
BioLife Solutions
(NASDAQ:BLFS)
Select Model
Select Model
Rating:70Outperform
Price Target:
$38.00
▲(2.10% Upside)
Action:Upgraded
Date:09/10/26
The score is driven primarily by improving financial performance and a notably strong balance sheet, with a positive M&A backdrop adding support. Offsetting factors are mixed near-term technicals and a relatively high P/E with no dividend, plus lingering concerns around cash conversion given negative TTM free cash flow.
Positive Factors
Recurring biopreservation workflow demand
BioLife serves recurring needs across biologics handling, cell therapy manufacturing, cryopreservation, and transport. Consumables and workflow products can generate repeat demand as customers advance programs from research into clinical and commercial production, supporting durable customer relationships and revenue expansion.
Negative Factors
Negative free cash flow despite reported profit
Although operating cash flow has improved, negative TTM free cash flow shows that capital expenditure or working-capital requirements are still absorbing cash. The gap between accounting profit and cash generation could limit internally funded investment and makes the quality of the recent earnings improvement less certain.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring biopreservation workflow demand
BioLife serves recurring needs across biologics handling, cell therapy manufacturing, cryopreservation, and transport. Consumables and workflow products can generate repeat demand as customers advance programs from research into clinical and commercial production, supporting durable customer relationships and revenue expansion.
Read all positive factors
BioLife Solutions (BLFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.73B
Dividend YieldN/A
Average Volume (3M)778.21K
Price to Earnings (P/E)33.8
Beta (1Y)1.41
Revenue Growth0.17%
EPS GrowthN/A
CountryUS
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.03
Shares Outstanding48,923,332
10 Day Avg. Volume921,864
30 Day Avg. Volume778,211
Financial Highlights & Ratios
PEG Ratio2.24
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio2.78K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$31.00Price Target Upside-16.71% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.54
Revenue Forecast (FY)$114.65M
BioLife Solutions Business Overview & Revenue Model
Company Description
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle E...
How the Company Makes Money
BioLife Solutions makes money primarily by selling products and services that support customers’ biologics workflows before, during, and after cryopreservation and transport. Key revenue streams include: (1) Consumable and recurring-use products: ...
BioLife Solutions Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call presented a constructive growth story highlighted by strong top-line performance (Q1 revenue +25%), improved profitability in absolute dollars (adjusted EBITDA up ~15%, GAAP net income positive), clear market leadership in BPM with robust pipeline visibility, and reaffirmed full-year guidance. Key operational challenges—most notably bag yield/scrap issues that compressed gross margin and adjusted EBITDA margin, rising operating expenses tied to R&D and severance, short-term cash/working capital pressures, and customer/product concentration—represent meaningful near-term risks but are described as manageable and temporary by management. Given the combination of durable demand drivers, strategic initiatives (product launches, cross-sell opportunities) and a solid balance sheet, the positive growth and leadership signals outweigh the transitory operational headwinds in management's view.Positive Updates
Strong Q1 Revenue Growth
Total revenue of $27.5 million in Q1 2026, up 25% year-over-year, driven primarily by biopreservation media (BPM) and growth across the product portfolio.
Negative Updates
Bag Yield Issues Driving Margin Pressure
Adjusted gross margin declined to 64% in Q1 2026 from 68% in Q1 2025 (GAAP gross margin 64% vs 67% prior). The decline is primarily attributed to a product mix shift toward bags and manufacturing yield/scrap issues tied to bags. Management views the yield impact as transitory but expects margin improvement only after customers select alternatives and existing bag inventory is consumed (estimated flow-through in Q4 2026 or Q1 2027).
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue Growth
Total revenue of $27.5 million in Q1 2026, up 25% year-over-year, driven primarily by biopreservation media (BPM) and growth across the product portfolio.
Read all positive updates
Company Guidance
BioLife reiterated 2026 guidance of $112.5–$115.0 million in revenue (growth of ~17%–20% YoY), GAAP and adjusted gross margins in the mid‑60s, an expected expansion in adjusted EBITDA margin versus 2025, and the achievement of full‑year positive GAAP net income for the first time in many years; for context, Q1 revenue was $27.5M (+25% YoY) with adjusted EBITDA of $6.2M (22% of revenue) and adjusted gross margin of 64%, cash and marketable securities of $111.5M at March 31, 2026, shares outstanding of 48.9M (50.3M fully diluted) as of April 30, and management expects bag‑yield remediation to drive margin improvement by Q4 2026 (or Q1 2027).BioLife Solutions Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 102.82M | 96.21M | 82.25M | 68.02M | 76.24M | 119.16M |
| Gross Profit | 66.30M | 62.12M | 53.67M | 41.32M | 46.91M | 37.05M |
| EBITDA | 9.78M | 3.61M | 1.53M | -7.10M | -3.10M | -17.78M |
| Net Income | 50.45M | -12.13M | -20.18M | -68.00M | -139.81M | -8.91M |
Balance Sheet | ||||||
| Total Assets | 447.49M | 405.88M | 399.49M | 412.71M | 450.23M | 554.29M |
| Cash, Cash Equivalents and Short-Term Investments | 82.42M | 88.93M | 104.58M | 44.18M | 62.70M | 69.86M |
| Total Debt | 15.74M | 17.90M | 30.17M | 33.83M | 43.71M | 26.88M |
| Total Liabilities | 27.49M | 34.00M | 50.58M | 75.05M | 86.04M | 76.24M |
| Stockholders Equity | 420.00M | 371.89M | 348.91M | 337.66M | 364.19M | 478.05M |
Cash Flow | ||||||
| Free Cash Flow | -904.00K | 416.00K | 5.20M | -18.88M | -18.87M | -13.22M |
| Operating Cash Flow | 16.88M | 20.11M | 8.43M | -12.50M | -8.49M | -4.84M |
| Investing Cash Flow | -8.24M | -71.54M | 58.30M | 17.84M | -58.12M | -12.64M |
| Financing Cash Flow | -16.54M | -10.92M | -6.78M | 10.59M | 16.32M | -2.78M |
BioLife Solutions Technical Analysis
Neutral
37.22
Price Trends
32.66
Positive
28.34
Positive
25.55
Positive
Market Momentum
0.75
Positive
50.38
Neutral
14.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Neutral. The current price of 37.22 is above the 20-day moving average (MA) of 36.04, above the 50-day MA of 32.66, and above the 200-day MA of 25.55, indicating a neutral trend. The MACD of 0.75 indicates Positive momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 14.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLFS.
BioLife Solutions Risk Analysis
BioLife Solutions disclosed 38 risk factors in its most recent earnings report. BioLife Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLife Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.73B | 33.78 | 13.29% | ― | 0.17% | ― | |
59 Neutral | $322.04M | -9.42 | -473.55% | 0.00% | 12.93% | -219.19% | |
59 Neutral | $1.50B | -9.95 | -58.76% | ― | 59.03% | 2.13% | |
58 Neutral | $3.48B | -45.27 | -94.42% | ― | ― | -11.31% | |
55 Neutral | $1.35B | -10.96 | -7.56% | 0.37% | 1.47% | -9.38% | |
55 Neutral | $1.21B | 295.25 | 1.08% | ― | 51.30% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BLFS
BioLife Solutions
34.93
8.44
31.86%
AZTA
Azenta
30.15
0.87
2.97%
STAA
Staar Surgical
23.62
-4.04
-14.61%
PLSE
Pulse Biosciences
52.97
38.20
258.63%
SMTI
Sanara MedTech
35.03
1.27
3.76%
KMTS
Kestra Medical Technologies Ltd.
24.07
5.88
32.33%
BioLife Solutions Corporate Events
M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
BioLife Solutions Nears Completion of Repligen Acquisition
Positive
Sep 9, 2026
On July 21, 2026, BioLife Solutions, Inc. agreed to be acquired by bioprocessing specialist Repligen Corporation in a cash-and-stock transaction in which BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock f...
Business Operations and StrategyM&A Transactions
BioLife Details Strategic Repligen Merger Communication to Staff
Positive
Aug 3, 2026
On July 21, 2026, BioLife Solutions entered into a merger agreement with Repligen under which BioLife will first merge into a Repligen subsidiary and become a wholly owned unit, followed by a second merger that will fold BioLife into another Repli...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
BioLife Solutions to Be Acquired by Repligen Corporation
Positive
Jul 22, 2026
On July 21, 2026, BioLife Solutions entered into a merger agreement under which Repligen Corporation will acquire all outstanding BioLife shares for $11.25 in cash and 0.1442 Repligen shares per BioLife share, valuing the deal at about $1.5 billio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.